MedTrace Logo

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

NCT04156256 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-11-12

No results posted yet for this study

Summary

Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD123-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.

Conditions

Interventions

BIOLOGICAL

CD123-CD33 cCAR T cells

CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.

Sponsors & Collaborators

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Chengdu Military General Hospital

    collaborator OTHER

  • iCAR Bio Therapeutics Ltd.

    collaborator INDUSTRY

  • iCell Gene Therapeutics

    lead INDUSTRY

Principal Investigators

  • Hongyu Zhang, MD, PhD · Peking University Shenzhen Hospital

  • Fang Liu, MD, PhD · Chengdu Military General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04156256 on ClinicalTrials.gov